Diplomat Pharmacy Faces Shareholder Suit Over Value Drop

By Cara Mannion · November 14, 2016, 6:22 PM EST

Specialty drugmaker Diplomat Pharmacy Inc. overestimated its hepatitis C drug's financial outlook and failed to properly calculate $8 million in Medicare fees, causing share values to plummet by 42 percent once...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Zimmerman v. Diplomat Pharmacy, Inc. et al

Case Number

Court

Michigan Eastern

Nature of Suit

Securities/Commodities

Date Filed

November 10, 2016

Recent Articles By Cara

June 16, 2017
Amedisys Pays $44M To End Investors' Medicare Fraud Suit
May 23, 2017
$30M Rx Service Investor Double-Crossed, Suit Says
March 22, 2017
Ex-Pot Dispenser Exec Pays SEC $12M Over Fraudulent Sales
March 14, 2017
Wells Fargo Yielded Verdict's Preclusion Of Fiduciary Claims
February 24, 2017
Cynosure Investors Sue To Block $1.4B Hologic Merger
February 03, 2017
Greenberg Traurig Settles Clawback Suit Over $2.2M In Fees
December 09, 2016
Express Scripts Says Stockholder Suit Lacks Fraud Proof
December 07, 2016
Man Who Posed As Gov't Official Gets 5 Years For $26M Fraud
August 19, 2016
Sheppard Mullin Adds Crowell & Moring Gov't Contracts Pro